Loading
Surface Oncology made antibodies meant to break down the defences tumours build around themselves against the immune system. Coherus BioSciences bought it in 2023.
Surface Oncology was a clinical-stage immuno-oncology company developing immunotherapies that target the tumour microenvironment. Coherus BioSciences closed its acquisition on 8 September 2023, issuing 0.1960 Coherus shares per Surface share. The assets that came from Surface were casdozokitug (SRF388), an IL-27-targeted antibody then in Phase 2 trials in lung cancer and liver cancer, and SRF114, an ADCC-enhanced CCR8-targeted antibody in a Phase 1/2 study in advanced solid tumours. Atlas Venture lists Surface as developing antibodies to break through the tumour microenvironment, sold to Coherus in 2023.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/